Mass Spectrometric Identification and Molecular Modeling of Glycopeptides Presented by MHC Class I and II Processing Pathways
Aberrant glycosylation is a hallmark of cancer that contributes to the disease’s ability to evade the immune system. As the MHC processing pathways communicate cellular health to circulating CD8+ and CD4+ T-cells, MHC-associated glycopeptides are likely a source of neoantigens in cancer. In fact, recent advances in mass spectrometry have allowed for the detection and sequencing of tumor-specific glycopeptides from the MHC class I and class II processing pathways. Here, we describe methods for detecting, sequencing, and modeling these MHC-associated glycopeptides.
Key wordsMass spectrometry MHC-associated glycopeptides Glycopeptide analysis Neoantigens Molecular modeling
The authors would like to acknowledge Jane V. Aldrich (U Florida), Dina L. Bai, Jeffrey Shabanowitz, and Donald F. Hunt (U Virginia) for their technical and financial support. This work was supported by a research grant from the Melanoma Research Alliance and by an NIH grant AI033993 to D.F.H. S.A.M. is currently funded by an NIH F32 Postdoctoral fellowship.
- 11.Bern M, Kil YJ, Becker C (2012) Byonic: advanced peptide and protein identification software. Curr Protoc Bioinformatics 13:Unit 13.20Google Scholar
- 15.Molecular Operating Environment (MOE), 2014.09; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2015Google Scholar